Treatment of Hereditary Hemochromatosis in Severe Anemia or Congestive Heart Failure

In patients with hereditary hemochromatosis (HH) who also have severe anemia or congestive heart failure, the standard approach to iron removal may itself carry a significant risk of harm, requiring a distinct therapeutic strategy.

Clinical Scenario

Phlebotomy is the conventional first step in managing systemic iron overload in HH. However, when a patient presents with severe anemia or congestive heart failure, phlebotomy carries the potential to worsen their condition. In this setting — or when a patient is intolerant or refractory to phlebotomy — an alternative iron-reduction strategy is strongly indicated.

Treatment Approach

Iron chelation therapy is strongly recommended for this patient population. The full protocol details which specific chelating agents are available, as well as the evidence supporting their use — but the complete regimen, agent selection, and clinical guidance are in the structured protocol.

Full regimen details, agent options, and clinical decision pathway available via the link below.

Clinical Goals

The primary therapeutic targets are meaningful reduction in serum ferritin levels and hepatic iron concentration, assessed over the course of treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000000315

We recommend the use of iron chelation for the treatment of HH for the patient who is intolerant or refractory to phlebotomy or when phlebotomy has the potential for harm, such as in patients with severe anemia or congestive heart failure (strong recommendation, low quality of evidence).

After 12 months of treatment, deferasirox achieved reduction in median ferritin levels and HIC and was well tolerated (148).

View source ↗